Temporary 2-week suspension of methotrexate treatment to enhance COVID-19 vaccine response in people with immune-mediated inflammatory diseases: the VROOM RCT
(2025)
Journal Article
Abhishek, A., Peckham, N., Pade, C., Gibbons, J. M., Cureton, L., Reynolds, C. J., Francis, A., Barber, V., Williams, J., Appelbe, D., Eldridge, L., Julier, P., Altmann, D. M., Bluett, J., Brooks, T., Coates, L. C., Rombach, I., Semper, A., Otter, A., Valdes, A. M., …Cook, J. A. (2025). Temporary 2-week suspension of methotrexate treatment to enhance COVID-19 vaccine response in people with immune-mediated inflammatory diseases: the VROOM RCT. Efficacy and Mechanism Evaluation, 1-42. https://doi.org/10.3310/kytk6537
Objective
Methotrexate is first-line treatment for many immune-mediated inflammatory diseases. However, it inhibits vaccine-induced immunity – a major concern for this vulnerable group of patients. We evaluated if a 2-week interruption of methotrexa...
Read More about Temporary 2-week suspension of methotrexate treatment to enhance COVID-19 vaccine response in people with immune-mediated inflammatory diseases: the VROOM RCT.